NEW YORK (GenomeWeb News) – Indi Molecular said today that it has raised $300,000 from a new investor, Asset Management Ventures.

With this investment, Indi Molecular has expanded the amount raised in its seed round to a total of $1.8 million, which it will use to further development of its protein catalyzed capture reagents, a synthetic affinity agent technology that the company hopes to market as an alternative to traditional antibodies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: issues in reproducibility, circulating DNA predicts breast cancer relapse, and more.

Because of an autoimmune disorder, a man has been shedding live polioviruses for 28 years, according to an analysis appearing in PLOS Pathogens.

Being in a long-term collaboration can increase researchers' citation rates by 17 percent, a recent analysis says.

By analyzing tweets, Canadian researchers examine the public's view of gene patenting.